Limits...
Anticoagulant effect and safety assessment of an aqueous extract of Pseudocedrela kotschyi (Schweinf.) harms and Adenia cissampeloides (Planch. Ex Hook.) harms.

Nyansah WB, Koffuor GA, Asare F, Gyanfosu L - J Intercult Ethnopharmacol (2016)

Bottom Line: The PAE treatment resulted in a significant increase (P ≤ 0.05-0.0001) in BT and CT in vivo compared with control.The no-observed-adverse-effect-level was <2000 mg/kg when given orally.PAE has anticoagulant effect in vitro and is safe to use at oral doses <2000 mg/kg.

View Article: PubMed Central - PubMed

Affiliation: Department of Pharmacology, Faculty of Pharmacy and Pharmaceutical Sciences, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.

ABSTRACT

Background: Currently available therapeutic options for thromboembolic disorders are often very expensive and are associated with unfavorable side effects.

Aim: To establish the anticoagulant effect and safety profile of an extract made from of the root bark of Pseudocedrela kotschyi (Schweinf.) Harms and the aerial part of Adenia cissampeloides (Planch. ex Hook.) Harms (PAE).

Materials and methods: PAE (0.5-2.0 g/L) effect on prothrombin time (PT) and activated partial thromboplastin time (aPTT) were evaluated on whole blood drawn from the marginal ear vein of New Zealand White rabbits. Effect of PAE (250-2000 mg/kg) on bleeding time (BT) and clotting time (CT) in Sprague-Dawley rats were also assessed. Histopathological, hematological, and liver function studies were also carried out to assess the safety for use of PAE (250-2000 mg/kg).

Results: PAE had no significant effect (P > 0.05) on PT, but resulted in a significant increase (P ≤ 0.05-0.0001) in aPTT. The PAE treatment resulted in a significant increase (P ≤ 0.05-0.0001) in BT and CT in vivo compared with control. Safety studies indicated no deaths with PAE treatment with hematological and liver function tests being normal. Histological studies revealed pathological changes in the liver at a PAE treatment dose of 2000 mg/kg but all doses had no detrimental effect on kidney and stomach tissue. The no-observed-adverse-effect-level was <2000 mg/kg when given orally.

Conclusion: PAE has anticoagulant effect in vitro and is safe to use at oral doses <2000 mg/kg.

No MeSH data available.


Related in: MedlinePlus

The effect of rivaroxaban, aspirin, heparin, dalteparin and PAE on activated partial thromboplastin time (aPTT). Values plotted are means ± standard error of the mean; (n = 5), ****P ≤ 0.0001; **P ≤ 0.01; *P ≤ 0.05; ns P > 0.05 compared to control (One-way ANOVA followed by Sidak’s post hoc test). ††††P ≤ 0.0001; †††P = 0.0001; ††P ≤ 0.01 comparison between the two doses of same treatment
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4835990&req=5

Figure 3: The effect of rivaroxaban, aspirin, heparin, dalteparin and PAE on activated partial thromboplastin time (aPTT). Values plotted are means ± standard error of the mean; (n = 5), ****P ≤ 0.0001; **P ≤ 0.01; *P ≤ 0.05; ns P > 0.05 compared to control (One-way ANOVA followed by Sidak’s post hoc test). ††††P ≤ 0.0001; †††P = 0.0001; ††P ≤ 0.01 comparison between the two doses of same treatment

Mentions: Positive controls (rivaroxaban 0.01 mg/ml, aspirin 0.075 mg/ml, heparin 5 IU/L and dalteparin 5 IU/L) and PAE (0.5 g/L) showed no significant difference in aPTT compared with control, baseline aPTT was 85.91 ± 1.25 s. There was, however, an increase in aPTT resulting in a significant difference compared with control at treatment doses of 0.1 mg/ml rivaroxaban, 0.75 mg/ml aspirin, 50 IU/l heparin and 50 IU/L dalteparin. PAE at (1.0, 1.5 and 2.0 g/L) also showed a significant increase (P ≤ 0.05 - 0.0001, respectively) compared with control [Figure 3].


Anticoagulant effect and safety assessment of an aqueous extract of Pseudocedrela kotschyi (Schweinf.) harms and Adenia cissampeloides (Planch. Ex Hook.) harms.

Nyansah WB, Koffuor GA, Asare F, Gyanfosu L - J Intercult Ethnopharmacol (2016)

The effect of rivaroxaban, aspirin, heparin, dalteparin and PAE on activated partial thromboplastin time (aPTT). Values plotted are means ± standard error of the mean; (n = 5), ****P ≤ 0.0001; **P ≤ 0.01; *P ≤ 0.05; ns P > 0.05 compared to control (One-way ANOVA followed by Sidak’s post hoc test). ††††P ≤ 0.0001; †††P = 0.0001; ††P ≤ 0.01 comparison between the two doses of same treatment
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4835990&req=5

Figure 3: The effect of rivaroxaban, aspirin, heparin, dalteparin and PAE on activated partial thromboplastin time (aPTT). Values plotted are means ± standard error of the mean; (n = 5), ****P ≤ 0.0001; **P ≤ 0.01; *P ≤ 0.05; ns P > 0.05 compared to control (One-way ANOVA followed by Sidak’s post hoc test). ††††P ≤ 0.0001; †††P = 0.0001; ††P ≤ 0.01 comparison between the two doses of same treatment
Mentions: Positive controls (rivaroxaban 0.01 mg/ml, aspirin 0.075 mg/ml, heparin 5 IU/L and dalteparin 5 IU/L) and PAE (0.5 g/L) showed no significant difference in aPTT compared with control, baseline aPTT was 85.91 ± 1.25 s. There was, however, an increase in aPTT resulting in a significant difference compared with control at treatment doses of 0.1 mg/ml rivaroxaban, 0.75 mg/ml aspirin, 50 IU/l heparin and 50 IU/L dalteparin. PAE at (1.0, 1.5 and 2.0 g/L) also showed a significant increase (P ≤ 0.05 - 0.0001, respectively) compared with control [Figure 3].

Bottom Line: The PAE treatment resulted in a significant increase (P ≤ 0.05-0.0001) in BT and CT in vivo compared with control.The no-observed-adverse-effect-level was <2000 mg/kg when given orally.PAE has anticoagulant effect in vitro and is safe to use at oral doses <2000 mg/kg.

View Article: PubMed Central - PubMed

Affiliation: Department of Pharmacology, Faculty of Pharmacy and Pharmaceutical Sciences, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.

ABSTRACT

Background: Currently available therapeutic options for thromboembolic disorders are often very expensive and are associated with unfavorable side effects.

Aim: To establish the anticoagulant effect and safety profile of an extract made from of the root bark of Pseudocedrela kotschyi (Schweinf.) Harms and the aerial part of Adenia cissampeloides (Planch. ex Hook.) Harms (PAE).

Materials and methods: PAE (0.5-2.0 g/L) effect on prothrombin time (PT) and activated partial thromboplastin time (aPTT) were evaluated on whole blood drawn from the marginal ear vein of New Zealand White rabbits. Effect of PAE (250-2000 mg/kg) on bleeding time (BT) and clotting time (CT) in Sprague-Dawley rats were also assessed. Histopathological, hematological, and liver function studies were also carried out to assess the safety for use of PAE (250-2000 mg/kg).

Results: PAE had no significant effect (P > 0.05) on PT, but resulted in a significant increase (P ≤ 0.05-0.0001) in aPTT. The PAE treatment resulted in a significant increase (P ≤ 0.05-0.0001) in BT and CT in vivo compared with control. Safety studies indicated no deaths with PAE treatment with hematological and liver function tests being normal. Histological studies revealed pathological changes in the liver at a PAE treatment dose of 2000 mg/kg but all doses had no detrimental effect on kidney and stomach tissue. The no-observed-adverse-effect-level was <2000 mg/kg when given orally.

Conclusion: PAE has anticoagulant effect in vitro and is safe to use at oral doses <2000 mg/kg.

No MeSH data available.


Related in: MedlinePlus